Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

DNA
(Shutterstock)

Sangamo Therapeutics’ efforts to secure a partnership for ST-920 (isaralgagene civoparvovec), its gene therapy for Fabry disease, should get easier now that the biotech has positive pivotal data supporting a US Food and Drug Administration filing.

Key Takeaways
  • Sangamo unveiled positive data from the pivotal STAAR trial of ST-920 and plans to seek approval for the therapy in Fabry disease in 2026.  

The Richmond, Calif.-based, gene therapy-focused biotech said June 24 that the pivotal Phase I/II STAAR study met the endpoint –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gene Therapies

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Rocket Comes Back To Earth With Restructuring Plan

 

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Sarepta Voluntarily Stops Shipments Of Elevidys After Previously Refusing FDA Request

 
• By 

The company had planned to keep its DMD gene therapy available for ambulatory patients, but now says pausing shipments may enable a better working relationship with the US FDA while safety labeling is updated.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.